The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Genetics of hepatocellular tumors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3)
Yamagata, K., Oda, N., Kaisaki, P. J., Menzel, S., Furuta, H., Vaxillaire, M., Southam, L., Cox, R. D., Lathrop, G. M., Boriraj, V. V., et al. (1996) · Nature · doi:10.1038/384455a0 · Cited by 1,614
Mutational hot spot in the p53 gene in human hepatocellular carcinomas
Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,534
Mutations of mitotic checkpoint genes in human cancers
Cahill, D. P., Lengauer, C., Yu, J., Riggins, G. J., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/32688 · Cited by 1,486
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,432
Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas
Coste, A. D. L., Romagnolo, B., Billuart, P., Renard, C.-A., Buendia, M.-A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8847 · Cited by 1,121
Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., et al. (2000) · Nature Genetics · doi:10.1038/73448 · Cited by 960
Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways
Lagna, G., Hata, A., Hemmati-Brivanlou, A., & Massagué, J. (1996) · Nature · doi:10.1038/383832a0 · Cited by 905
Cited by
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Self-citationFujimoto, A., Totoki, Y., Abe, T., Boroevich, K. A., Hosoda, F., Nguyen, H. H., Aoki, M., Hosono, N., Kubo, M., Miya, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2291 · Cited by 870
Ladeiro, Y., Couchy, G., Balabaud, C., Bioulac-Sage, P., Pelletier, L., Rebouissou, S., & Zucman-Rossi, J. (2008) · Hepatology · doi:10.1002/hep.22256 · Cited by 684
Self-citationSelf-renewing diploid Axin2+ cells fuel homeostatic renewal of the liver
Wang, B., Zhao, L., Fish, M., Logan, C. Y., & Nusse, R. (2015) · Nature · doi:10.1038/nature14863 · Cited by 674
The H19 Non-Coding RNA Is Essential for Human Tumor Growth
Matouk, I. J., DeGroot, N., Mezan, S., Ayesh, S., Abu-lail, R., Hochberg, A., & Galun, E. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000845 · Cited by 650
Structure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 434
Mechanisms of HBV-related hepatocarcinogenesis
Neuveut, C., Wei, Y., & Buendia, M. A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.033 · Cited by 421
Inflammation and Liver Cancer: New Molecular Links
Berasain, C., Castillo, J., Perugorria, M. J., Latasa, M. U., Prieto, J., & Avila, M. A. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03704.x · Cited by 390
Louandre, C., Marcq, I., Bouhlal, H., Lachaier, E., Godin, C., Saidak, Z., François, C., Chatelain, D., Debuysscher, V., Barbare, J.-C., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.014 · Cited by 374
Experimental mouse models for hepatocellular carcinoma research
Heindryckx, F., Colle, I., & Van Vlierberghe, H. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00656.x · Cited by 367
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
The epidermal growth factor receptor: from development to tumorigenesis
Sibilia, M., Kroismayr, R., Lichtenberger, B. M., Natarajan, A., Hecking, M., & Holcmann, M. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00238.x · Cited by 340
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
Vilchez, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.823 · Cited by 312
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
Comparison of hepatocellular carcinoma in Eastern versus Western populations
Choo, S. P., Tan, W. L., Goh, B. K. P., Tai, W. M., & Zhu, A. X. (2016) · Cancer · doi:10.1002/cncr.30237 · Cited by 264
Zucman-Rossi, J., Benhamouche, S., Godard, C., Boyault, S., Grimber, G., Balabaud, C., Cunha, A. S., Bioulac-Sage, P., & Perret, C. (2007) · Oncogene · doi:10.1038/sj.onc.1209824 · Cited by 256
Self-citationCanonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells
Yuzugullu, H., Benhaj, K., Ozturk, N., Senturk, S., Celik, E., Toylu, A., Tasdemir, N., Yilmaz, M., Erdal, E., Akcali, K. C., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-90 · Cited by 215
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma
Bengochea, A., de Souza, M. M., Lefrançois, L., Le Roux, E., Galy, O., Chemin, I., Kim, M., Wands, J. R., Trepo, C., Hainaut, P., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604422 · Cited by 215
“In parallel, we have shown that the WNT/FZD/sFRP expression patterns did not correlate to the TP53 and b-catenin gene mutation status in the HCC samples, these genes being the most frequently altered tumour suppressor and proto-oncogene in HCC (Laurent-Puig and Zucman-Rossi, 2006).”
Cholestasis is a marker for hepatocellular carcinomas displaying β‐catenin mutations
Audard, V, Grimber, G., Elie, C., Radenen, B., Audebourg, A., Letourneur, F., Soubrane, O., Vacher‐Lavenu, M., Perret, C., Cavard, C., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2169 · Cited by 162
Wnt/β-Catenin Signaling in Liver Cancers
Wang, W., Smits, R., Hao, H., & He, C. (2019) · Cancers · doi:10.3390/cancers11070926 · Cited by 143
Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis
Dong, B., Lee, J.-S., Park, Y.-Y., Yang, F., Xu, G., Huang, W., Finegold, M. J., & Moore, D. D. (2015) · Nature Communications · doi:10.1038/ncomms6944 · Cited by 97
“The clear association of these mouse tumors with β -catenin activated HCC, which accounts for a significant fraction of human HCC 55, 56 , makes this new model a powerful tool for tumor prevention and treatment studies with direct relevance to human HCC.”
E2f8 mediates tumor suppression in postnatal liver development
Kent, L. N., Rakijas, J. B., Pandit, S. K., Westendorp, B., Chen, H.-Z., Huntington, J. T., Tang, X., Bae, S., Srivastava, A., Senapati, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85506 · Cited by 95
“…how the E2F program is coordinated during animal development is only beginning to emerge, it is clear that disruption of the RB-E2F transcriptional network is a critical event downstream of many genetic alterations that promote cancer development, including hepatocellular carcinoma (HCC) (18, 19).”
Diabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Hua, Y., Yang, Y., Li, Q., He, X., Zhu, W., Wang, J., & Gan, X. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004434 · Cited by 75
“Hyperactivation of WNT/ -catenin signaling has been considered as the major cause for hepatoma genesis; however, the mechanisms still remain unclear (31, 33).”
BackgroundHale, G., Liu, X., Hu, J., Xu, Z., Che, L., Solomon, D., Tsokos, C., Shafizadeh, N., Chen, X., Gill, R., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.122 · Cited by 73
“Hepatocellular carcinoma with β-catenin mutations are typically more well-differentiated, occur in non-cirrhotic liver, infrequently have TP53 mutations, have a lower level of chromosomal instability and a relatively better prognosis (15, 18, 19).”
Background
Metadata
- Authors
- Laurent-Puig, P., & Zucman-Rossi, J.
- Venue
- Oncogene
- Published
- 2006-06-26
- Volume
- 25
- Issue
- 27
- Pages
- 3778-3786
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2045844532
- Cited by
- 317
- References
- 75
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.